ArticleNeuro-oncology advances
Sonobiopsy for enrichment of circulating microRNAs in glioma patients.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Sonobiopsy is a promising new technique that employs focused ultrasound (FUS) to noninvasively enrich brain tumor-derived biomarkers from spatially targeted brain location into the bloodstream. Building upon our recent first-in-human sonobiopsy trial demonstrating enrichment of circulating tumor DNA (ctDNA), here we investigated whether sonobiopsy can enhance the release and detection of tumor-derived microRNAs (miRNAs). Methods: Eleven patients with glioma underwent FUS sonication immediately prior to surgical resection. Peripheral blood samples were collected 5 min before and 5, 10, and 30 min after sonication. Plasma and brain tissue miRNA levels were quantified through small RNA sequencing and compared among different time points. Results: Plasma miRNAs that were below the detection threshold [reads per million (RPM) <10] showed significant enrichment at all post-FUS time points across all patients, with a maximal increase of 8.7-fold at 30 min. In contrast, miRNAs above the detection threshold (RPM ≥10) exhibited no significant change following FUS. Among the miRNAs that were initially below the detection threshold but increased to detectable levels following sonobiopsy, miR-29c-5p, miR-125b-1-3p, miR-129-5p, miR-132-3p, miR-143-5p, miR-149-5p, miR-195-5p, miR-218-5p, miR-329-3p, and miR-1271-5p were associated with cancer- and glioma-related biological pathways. Conclusions: These findings extend our prior work and support sonobiopsy as a spatially targeted, noninvasive multimodal liquid biopsy platform. By increasing the detectability of otherwise difficult-to-detect tumor-derived signals, sonobiopsy has the potential to advance the development of sensitive molecular diagnostics for glioma without surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.